OPKO Health Q3 operating loss narrows

Overview

• Biopharmaceutical firm's Q3 revenue rose yr/yr

• Q3 operating loss narrowed compared to prior year

Outlook

• OPKO withdraws guidance for services revenue and total costs due to pending Labcorp transaction

• Company expects Q4 total revenue between $62 mln and $72 mln

• OPKO forecasts 2026 full-year revenue of $268 mln to $278 mln

Result Drivers

• ROYALTY AND PRODUCT SALES - Higher royalty revenue from Lilly, increased Rayaldee sales and growth in international operations drove revenue growth

• MEDICARE COVERAGE CHANGES - Rayaldee sales benefited from favorable gross-to-net adjustments related to Medicare coverage changes

• INTERNATIONAL GROWTH - Stronger performance in international markets, including animal health and favorable currency impacts, contributed to revenue gains

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for OPKO Health, Inc. is $3.00, about 74.4% above its November 3 closing price of $1.72

Reuters Recommended Reads

• Nov 4 - Royalty Pharma Q3 adjusted EBITDA beats estimates; raises 2026 guidance

• Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

• Nov 3 - Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)